Molecular Basis of Fibrinogen Naples Associated with Defective Thrombin Binding and Thrombophilia. Homozygous Substitution of B Beta 68 Ala----Thr

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1992 Jul 1

PMID 1634610

Citations 18

Authors

J Koopman

F Haverkate

S T Lord

J Grimbergen

P M Mannucci

Affiliations

Soon will be listed here.

Abstract

In an abnormal fibrinogen (fibrinogen Naples) associated with congenital thrombophilia we have identified a single base substitution (G----A) in the B beta chain gene that results in an amino acid substitution of alanine by threonine at position 68 in the B beta chain of fibrinogen. The propositus and two siblings were found to be homozygous for the mutation, whereas the parents and another sibling were found to be heterozygous. Individuals homozygous for the defect had a severe history of both arterial and venous thrombosis; heterozygous individuals had no clinical symptoms. The three homozygotes had a prolonged thrombin clotting time in plasma, whereas the heterozygotes had a normal thrombin clotting time. Fibrinopeptide A and B (FpA and FpB) release from purified fibrinogen by human alpha-thrombin was delayed in both the homozygous propositus and a heterozygous family member. Release of FpA from the normal and abnormal amino-terminal disulfide knot (NDSK) corresponded to that found with the intact fibrinogens, indicating a decreased interaction of thrombin with the NDSK part of fibrinogen Naples. Binding studies showed that fibrin from homozygous abnormal fibrinogen bound less than 10% of active site inhibited alpha-thrombin as compared with normal fibrin, while fibrin formed from heterozygous abnormal fibrinogen bound approximately 50% of alpha-thrombin. These results suggest that the mutation of B beta Ala 68----Thr affects the binding of alpha-thrombin to fibrin, and that defective binding results in a decreased release of FpA and FpB in both homozygous and heterozygous abnormal fibrinogens.

Citing Articles

Fibrinogen post-translational modifications are biochemical determinants of fibrin clot properties and interactions.

Tenopoulou M FEBS J. 2024; 292(1):11-27.

PMID: 39180244 PMC: 11705221. DOI: 10.1111/febs.17236.

Highly thrombogenic phenotype and impaired wound healing in a patient with congenital dysfibrinogenemia: case report.

El Beayni N, Szanto T, Neerman-Arbez M, Casini A, Lassila R Res Pract Thromb Haemost. 2024; 8(4):102469.

PMID: 39036671 PMC: 11259863. DOI: 10.1016/j.rpth.2024.102469.

[Phenotype and genotype analyses of two pedigrees with inherited fibrinogen deficiency].

Jia K, Su Z, Chen H, Zheng X, Zeng M, Zhang K Zhonghua Xue Ye Xue Za Zhi. 2024; 44(11):930-935.

PMID: 38185523 PMC: 10753259. DOI: 10.3760/cma.j.issn.0253-2727.2023.11.008.

Fibrinogen BOE II: dysfibrinogenemia with bleeding and defective thrombin binding.

Li Y, Liang Q, Wu W, Hu X, Wang H, Wang X Res Pract Thromb Haemost. 2023; 7(5):102145.

PMID: 37601017 PMC: 10439445. DOI: 10.1016/j.rpth.2023.102145.

[Analysis of a family with congenital hypodysfibrinogenemia presented with thrombosis].

Wei C, Cai H, Hua B, Zhu T Zhonghua Xue Ye Xue Za Zhi. 2023; 43(10):865-869.

PMID: 36709203 PMC: 9669631. DOI: 10.3760/cma.j.issn.0253-2727.2022.10.012.

References

Saiki R, Gelfand D, Stoffel S, Scharf S, Higuchi R, Horn G . Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988; 239(4839):487-91. DOI: 10.1126/science.2448875. View

Haverkate F, Koopman J, Kluft C, DAngelo A, Cattaneo M, Mannucci P . Fibrinogens "Milano II"- and "Naples". Thromb Haemost. 1987; 57(3):375. View

Engesser L, Koopman J, de Munk G, Haverkate F, Novakova I, Verheijen J . Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. Thromb Haemost. 1988; 60(1):113-20. View

Ruf W, Bender A, Lane D, Preissner K, Selmayr E, Muller-Berghaus G . Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization. Biochim Biophys Acta. 1988; 965(2-3):169-75. DOI: 10.1016/0304-4165(88)90053-0. View

Liu C, Koehn J, Morgan F . Characterization of fibrinogen New York 1. A dysfunctional fibrinogen with a deletion of B beta(9-72) corresponding exactly to exon 2 of the gene. J Biol Chem. 1985; 260(7):4390-6. View

Southan C, Lane D, Bode W, Henschen A . Thrombin-induced fibrinopeptide release from a fibrinogen variant (fibrinogen Sydney I) with an Aalpha Arg-16----His substitution. Eur J Biochem. 1985; 147(3):593-600. DOI: 10.1111/j.0014-2956.1985.00593.x. View

Haverkate F, Koopman J, Kluft C, DAngelo A, Cattaneo M, Mannucci P . Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis. Thromb Haemost. 1986; 55(1):131-5. View

Rixon M, Chung D, Davie E . Nucleotide sequence of the gene for the gamma chain of human fibrinogen. Biochemistry. 1985; 24(8):2077-86. DOI: 10.1021/bi00329a041. View

Fenton 2nd J, Olson T, Zabinski M, Wilner G . Anion-binding exosite of human alpha-thrombin and fibrin(ogen) recognition. Biochemistry. 1988; 27(18):7106-12. DOI: 10.1021/bi00418a066. View

10.

Vali Z, Scheraga H . Localization of the binding site on fibrin for the secondary binding site of thrombin. Biochemistry. 1988; 27(6):1956-63. DOI: 10.1021/bi00406a023. View

11.

Gustafson S, Proper J, BOWIE E, Sommer S . Parameters affecting the yield of DNA from human blood. Anal Biochem. 1987; 165(2):294-9. DOI: 10.1016/0003-2697(87)90272-7. View

12.

Kaminski M, McDonagh J . Inhibited thrombins. Interactions with fibrinogen and fibrin. Biochem J. 1987; 242(3):881-7. PMC: 1147791. DOI: 10.1042/bj2420881. View

13.

Berliner L, Sugawara Y, Fenton 2nd J . Human alpha-thrombin binding to nonpolymerized fibrin-Sepharose: evidence for an anionic binding region. Biochemistry. 1985; 24(24):7005-9. DOI: 10.1021/bi00345a038. View

14.

Lord S, Byrd P, Hede K, Wei C, Colby T . Analysis of fibrinogen A alpha-fusion proteins. Mutants which inhibit thrombin equivalently are not equally good substrates. J Biol Chem. 1990; 265(2):838-43. View

15.

Naski M, Shafer J . Alpha-thrombin-catalyzed hydrolysis of fibrin I. Alternative binding modes and the accessibility of the active site in fibrin I-bound alpha-thrombin. J Biol Chem. 1990; 265(3):1401-7. View

16.

Marsh Jr H, Meinwald Y, Thannhauser T, Scheraga H . Mechanism of action of thrombin on fibrinogen. Kinetic evidence for involvement of aspartic acid at position P10. Biochemistry. 1983; 22(18):4170-4. DOI: 10.1021/bi00287a002. View

17.

Hurlet-Jensen A, Cummins H, Nossel H, Liu C . Fibrin polymerization and release of fibrinopeptide B by thrombin. Thromb Res. 1982; 27(4):419-27. DOI: 10.1016/0049-3848(82)90059-7. View

18.

Kehl M, Lottspeich F, Henschen A . Analysis of human fibrinopeptides by high-performance liquid chromatography. Hoppe Seylers Z Physiol Chem. 1981; 362(12):1661-4. View

19.

Doolittle R . Fibrinogen and fibrin. Annu Rev Biochem. 1984; 53:195-229. DOI: 10.1146/annurev.bi.53.070184.001211. View

20.

Chung D, Que B, Rixon M, Mace Jr M, Davie E . Characterization of complementary deoxyribonucleic acid and genomic deoxyribonucleic acid for the beta chain of human fibrinogen. Biochemistry. 1983; 22(13):3244-50. DOI: 10.1021/bi00282a032. View